BioSpace News Archive

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that FDA has granted it clearance to proceed with TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with HER2-negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.

Accuray Incorporated announced that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration.

Protagonist Therapeutics, Inc. reported that on September 29, 2023, it issued inducement awards to Katharina Modelska, M.D., Ph.D., the Company’s recently hired Senior Vice President, Clinical Development, in accordance with the terms of Dr. Modelska’s employment offer letter.

Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, and Multipotent Adult Progenitor Cell technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health.

Natera, Inc., a global leader in cell-free DNA testing, announced that the United States Supreme Court denied CareDx, Inc.’s petition for certiorari concerning a patent infringement lawsuit brought by CareDx against Natera.

SciTech announced today that it has successfully manufactured the clinical supply of its lead drug candidate, ST-001 nanoFenretinide, to initiate its upcoming clinical trial in T-cell non-Hodgkin lymphomas (NCT04234048).

Blue Earth Diagnostics today announced results from a sub-group analysis from the Phase 3 LIGHTHOUSE trial (NC04186819) which evaluated the safety and diagnostic performance of POSLUMA® (flotufolastat F 18) PET in men with newly diagnosed prostate cancer.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 61,000 shares of Astria’s common stock on October 2, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Wayde McMillan has decided to step down from his role as Executive Vice President, Chief Financial Officer and Treasurer, effective October 20, 2023.

Centene Corporation announced that it will release its 2023 third quarter financial results at approximately 6 a.m. EDT on Tuesday, October 24, 2023, and will host a conference call afterwards at approximately 8:30 a.m. EDT to review the results.